A federal court ruled that the FDA could not prohibit Amarin Corp. from marketing its Vascepa drug for off-label use. The court says that doing so would be a violation of free speech.
A federal court ruled that the FDA could not prohibit Amarin Corp. from marketing its Vascepa drug for off-label use. The court says that doing so would be a violation of free speech.
Share this Article
Recommended